CVS Health’s $117B split: Defensive spin-off or end of healthcare vertical integration?

​CVS plans to divide its $117 billion empire into several entities by 2028. This may affect 9,000 pharmacies as well as such brands as Aetna and Caremark. The decision is a response to regulatory pressure on vertically integrated healthcare giants. Can this strategy provide a lasting shareholder value, or does it show the limitations of the conglomerate model in U.S. healthcare?

The structure of the breakup

CVS Health announced on Nov. 4, 2026, that it will be separated into two independent, publicly traded companies by the first half of 2028. One of them will retain the CVS Health brand name and will include Aetna, CVS Caremark, CVS Specialty, Oak Street Health, and Signify Health. The second one will be named CVS Pharmacy, with about 9,000 retail pharmacies, mail-order operations, MinuteClinic, and the Health100 technology platform. 

View post on X Loading...

The tweet was deleted by the author.

But we saved everything 🙂.

CEO David Joyner will lead the healthcare solutions company, and Group President Prem Shah will become CEO of CVS Pharmacy. The separation will be tax-free for shareholders, as both new companies should receive high investment-grade ratings and be able to pay dividends. Existing shareholders will receive stakes in both new entities.

“We take this action from a position of strength,” Joyner told investors. “We’re basically taking what I believe is one great company and making it two.”

Earnings strength fails to offset the surprise

The announcement came after third-quarter results that exceeded expectations. Revenue reached $108.4 billion, up 5.4% year over year. Adjusted earnings per share rose 30% to $2.09, versus the consensus of $1.65. Adjusted operating income increased by 21% to $4.2 billion. CVS raised full-year 2026 adjusted EPS guidance to $8.20 from $8.10 and revenue guidance to $420 billion. 

View post on X Loading...

The tweet was deleted by the author.

But we saved everything 🙂.

Operating cash flow is expected to reach $15.5 billion. Aetna’s Health Care Benefits adjusted operating income jumped to $912 million from $314 million a year earlier, and the medical benefit ratio reached 91.3%. Despite the positive dynamics, shares fell 12–13%. This resulted in the loss of $15 billion in market value and the market close near $80.

Regulatory pressure in the background

Management states that the decision is strategic rather than defensive. Joyner told analysts the company is “not doing anything out of a distressed decision” and that the businesses are strong enough to reach targets while working separately. However, analysts point to new regulatory requirements that could impact this move. In particular, Arkansas and Tennessee have passed laws restricting common ownership of PBMs and pharmacies. 

View post on X Loading...

The tweet was deleted by the author.

But we saved everything 🙂.

Federal proposals, including bipartisan legislation from Senators Josh Hawley and Elizabeth Warren, directly focus on PBM practices. The three largest players (CVS, UnitedHealth, and Cigna) control the majority of the PBM market. 

“The announced split of the company came as a surprise and is perceived as happening as a defensive move against regulation rather than an offensive move,” said UBS analyst Kevin Caliendo.

Analysts question the value case

Investors try to predict how debt, costs, and commercial agreements will be allocated. Barclays analyst Andrew Mok suggests that businesses should be able to operate successfully after the split. When CVS acquired Caremark two decades ago, management projected at least $500 million in annual synergy. Leerink’s Michael Cherny called the quarter “VERY strong” but noted that “so much of the focus shifts from fundamentals to the spin-off transaction.” 

View post on X Loading...

The tweet was deleted by the author.

But we saved everything 🙂.

RBC’s Ben Hendrix described it as “a somewhat surprising strategic departure from the integrated thesis” presented earlier to investors. The valuation proposes that a pure-play pharmacy may trade closer to retail peers, while the Aetna-Caremark platform may be closer to UnitedHealth or Cigna’s Evernorth. Execution risk and the consequences of the split remain uncertain.

Implications for U.S. and global healthcare

In the United States, the situation will prove whether vertical integration between insurers, PBMs, and pharmacies allows to achieve cost savings. It is possible that it merely concentrates market power. Aetna and Caremark may become integrated, while the retail layer will become closer to consumers and state regulators. Competitors may also have to follow a similar path if regulators continue to increase their pressure on the industry. 

View post on X Loading...

The tweet was deleted by the author.

But we saved everything 🙂.

Globally, the case may facilitate a tendency from healthcare conglomerates toward more open models with more intense competition. Multinational pharmacy chains and insurers may accelerate their reorganization in a similar direction. CVS’s split may demonstrate that operational focus and clear capital allocation outweigh the supposed benefits of integration. 

However, if it fails, it may demonstrate that political and regulatory pressure may lead to value-destroying separations. Regardless of the outcome, it will determine how the industry balances scale and regulation for many years.